PGNY Stock Analysis: Buy, Sell, or Hold?
PGNY - Progyny, Inc. Common Stock
$17.30
0.03 (0.17%)
▲
5d:
-3.94%
30d:
-2.2%
90d:
-32.95%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
PGNY is down 4.4% this week, but smart money is accumulating calls. Top strike: $22.5 2026-05-15 with 123 OI. Call ratio: 74% View Scanner →
Strength: 4.6/10
Get Alerted When PGNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PGNY appears deeply undervalued. Market expects -10.6% annual earnings decline despite 21% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: PGNY appears deeply undervalued. Market expects -10.6% annual earnings decline despite 21% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$34.72
Based on 7.6% avg growth
INTRINSIC VALUE TODAY
$21.56
19.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PGNY is currently trading at $17.30, which is considered slightly low relative to its 30-day fair value range of $17.34 to $20.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.2) compared to its historical average (11.5). Remarkably, the market is currently pricing in an annual earnings decline of 10.6% over the next few years. This pessimistic expectation contrasts with the company's recent 20.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PGNY is in a strong downtrend. The price is currently testing key support at $17.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.45 (+59.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PGNY is in a strong downtrend. The price is currently testing key support at $17.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.45 (+59.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$17.34 -
$20.42
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.0% below Wall St target ($27.45)
Fair Price Analysis
30-Day Fair Range
$17.34 -
$20.42
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$17.10
Resistance Level
$18.60
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.22
Wall Street Target
$27.45
(+59.0%)
Revenue Growth (YoY)
6.7%
Earnings Growth (YoY)
20.6%
Profit Margin
4.5%
Valuation Discount vs History
-10.6% cheaper
PE vs Historical
8.2 vs 11.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.6%
(market-implied from PE analysis)
1-Year Target
$15.54
(-10%)
2-Year Target
$13.99
(-19%)
3-Year Target
$12.59
(-27%)
3-Yr Target (if PE normalizes)
(PE: 8→12)
$17.61
(+2%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 11.1%)
$64.62
(+274%)
Base:
(SPY PE: 8.2, Growth: 11.1%)
$23.71
(+37%)
Bear:
(PE: 7.0, Growth: 11.1%)
$20.16
(+17%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 27.89 | Current EPS (TTM): $0.65
Bull Case
$39.89
(+122%)
Analyst growth 100.0%, PE expands to 30.7
Base Case
$36.26
(+101%)
Market implied 100.0%, PE stable at 27.9
Bear Case
$12.33
(-32%)
Severe decline -20.0%, PE contracts to 23.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.2 to 11.5
Stabilization Target:
$24.16
(+39.9%)
PE Expansion Potential:
+39.9%
Share & Embed Analysis
Last updated: March 30, 2026 11:52 AM ET
Data refreshes hourly during market hours. Next update: 12:52 PM
Data refreshes hourly during market hours. Next update: 12:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGNY showing a specific setup today?
Insider Activity (6 Months)
1
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Allison Swartz
SELL
599 shares
2026-03-04
Allison Swartz
SELL
4657 shares
2026-03-03
Allison Swartz
SELL
2199 shares
2026-03-02
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$97 | 57 HOLD |
|
CI
Cigna Corp |
STRONG BUY
25 analysts |
$339 | 63 BUY |
|
UNH
UnitedHealth Group Incor… |
STRONG BUY
27 analysts |
$361 | 47 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$381 | 60 BUY |
|
HUM
Humana Inc |
HOLD
26 analysts |
$212 | 59 HOLD |
Advanced PGNY Option Strategies
Professional options setups generated by AI based on today's PGNY price and gamma walls.
